[1]Medema RH, Lin CC, Yang JC.Polo-like kinase 1 inhibitors and their potential role in anticancer therapy,with a focus on NSCLC[J].Clin Cancer Res, 2011, 17(20):6459-6466[2]Li J, Wang J, Jiao H, et al.Cytokinesis and cancer: Polo loves ROCK'n' Rho(A)[J].J Genet Genomics, 2010, 37(3):159-172[3]Degenhardt Y, Lampkin T.Targeting Polo-like kinase in cancer therapy[J].Clin Cancer Res, 2010, 16(2):384-389[4]Strebhardt K, Ullrich A.Targeting polo-like kinase 1 for cancer therapy[J].Nat Rev Cancer, 2006, 6(4):321-330[5]Kneisel L, Strebhardt K, Bernd A, et al.Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease[J].J Cutan Pathol, 2002, 29(6):354-358[6]Schmit TL, Zhong W, Nihal M, et al.Polo-like kinase 1 (Plk1) in non-melanoma skin cancers[J].Cell Cycle, 2009, 8(17):2697-2702[7]周永静, 龚丹丹, 邱志远,等.特异性小干扰下调基因表达对黑素瘤黏附和侵袭的影响[J].中华皮肤科杂志, 2011, 44(7):497-500[8]Fan Y, Zhang YL, Wu Y, et al.Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells[J].World J Gastroenterol, 2008, 14(3):428-434[9]Frisch SM, Francis H.Disruption of epithelial cell-matrix interactions induces apoptosis[J].J Cell Biol, 1994, 124(4):619-626[10]Rosen K, Rak J, Leung T, et al.Activated ras prevents down-regulation of Bcl-XL triggered by detachment from the extracellular matrix: a TGF- -mediated mechanism of ras-induced resistance to anoikis in intestinal epithelial cells[J].J Cell Biol, 2000, 149(2):447-455[11]Zhu Z, Sanchez-Sweatman O, Huang X, et al.Anoikis and metastatic potential of cloudman S91 melanoma cells[J].Cancer Res, 2001, 61(4):1707-1716 |